My Portfolio
+
LINK YOUR PORTFOLIO

Inovio Pharmaceuticals Inc INO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:23 PM EDT
1.15quote price arrow down-0.06 (-4.96%)
Volume
1,228,036
52 week range
1.03 - 2.98
Loading...
  • Open1.21
  • Day High1.22
  • Day Low1.15
  • Prev Close1.21
  • 52 Week High2.98
  • 52 Week High Date09/09/25
  • 52 Week Low1.03
  • 52 Week Low Date04/10/26

Latest On Inovio Pharmaceuticals Inc

Key Stats

  • Market Cap94.614M
  • Shares Out82.27M
  • 10 Day Average Volume2.34M
  • Dividend-
  • Dividend Yield-
  • Beta1.47

Latest On Inovio Pharmaceuticals Inc

KEY STATS

  • Open1.21
  • Day High1.22
  • Day Low1.15
  • Prev Close1.21
  • 52 Week High2.98
  • 52 Week High Date09/09/25
  • 52 Week Low1.03
  • 52 Week Low Date04/10/26
  • Market Cap94.614M
  • Shares Out82.27M
  • 10 Day Average Volume2.34M
  • Dividend-
  • Dividend Yield-
  • Beta1.47

RATIOS/PROFITABILITY

  • EPS (TTM)-1.70
  • P/E (TTM)-0.68
  • Fwd P/E (NTM)-1.32
  • EBITDA (TTM)-82.358M
  • ROE (TTM)-296.36%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-130,006.00%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/10/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is...
Simon Benito
Independent Chairman of the Board
Jacqueline Shea Ph.D.
President, Chief Executive Officer, Director
Peter Kies
Chief Financial Officer
Address
660 W. Germantown Pike, Suite 110
Plymouth Meeting, PA
19462
United States